Lilly lifted by stronger-than-expected Mounjaro performance

2 November 2023
lilly_big

Eli Lilly (NYSE: LLY) has reported strong revenues for the third quarter, with blockbuster diabetes med Mounjaro (tirzepatide) doing much of the heavy lifting.

A stellar $1.4 billion in sales makes clear the trajectory of growth for the innovative product, which has only been available for a little over a year. Analysts had forecast sales of around $1.3 billion.

Other standout products include Verzenio (abemaciclib) and Jardiance (empagliflozin), with the $1.4 billion sale of rights for Zyprexa (olanzapine) also making a significant contribution to the balance sheet.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology